Extended-Release Viloxazine Compared with Atomoxetine for Attention Deficit Hyperactivity Disorder

A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial Assessing the Efficacy and Safety of Viloxazine Extended-Release Capsules in Adults with Attention-Deficit/Hyperactivity Disorder

(2022) Azmi Nasser et al.   CNS DRUGS

Viloxazine in the Management of CNS Disorders: A Historical Overview and Current Status

(2021) Robert L. Findling et al.   CNS DRUGS

α2-Adrenergic Agonists or Stimulants for Preschool-Age Children With Attention-Deficit/Hyperactivity Disorder

(2021) Elizabeth Harstad et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

A Phase III, Randomized, Placebo-Controlled Trial to Assess the Efficacy and Safety of Once-Daily SPN-812 (Viloxazine Extended-Release) in the Treatment of Attention-Deficit/Hyperactivity Disorder in School-age Children

(2020) Azmi Nasser et al.   CLINICAL THERAPEUTICS

Trends in stimulant dispensing by age, sex, state of residence, and prescriber specialty — United States, 2014–2019

(2020) Amy R. Board et al.   DRUG AND ALCOHOL DEPENDENCE

A critical appraisal of atomoxetine in the management of ADHD

(2015) Ann Childress   Therapeutics and Clinical Risk Management

Comparative Efficacy of Guanfacine Extended Release Versus Atomoxetine for the Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents: Applying Matching-Adjusted Indirect Comparison Methodology

(2013) Vanja Sikirica et al.   CNS DRUGS

A Comparison of the Efficacy of Medications for Adult Attention-Deficit/Hyperactivity Disorder Using Meta-Analysis of Effect Sizes

(2010) Stephen V. Faraone et al.   JOURNAL OF CLINICAL PSYCHIATRY

A retrospective claims analysis of combination therapy in the treatment of adult attention-deficit/hyperactivity disorder (ADHD)

(2009) Gerhardt M Pohl et al.   BMC HEALTH SERVICES RESEARCH

Validation of the Adult ADHD Investigator Symptom Rating Scale (AISRS)

(2009) Thomas J. Spencer et al.   Journal of Attention Disorders